Home » Healthcare » Pharmaceuticals » Chemotherapy Induced Nausea And Vomiting Treatment Market

Chemotherapy Induced Nausea And Vomiting Treatment Market By Patient Risk Profile (High-Risk Patients, Low-Risk Patients, Chemotherapy Regimen) By Administration Route (Oral Medications, Intravenous (IV) Medications) By Branded vs. Generic Products (Branded Medications, Generic Medications)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Published: | Report ID: 3998 | Report Format : PDF

Market Insights

  • The global demand for Chemotherapy-Induced Nausea and Vomiting Therapeutics  was valued at USD 5748.9 million in 2022 and is expected to reach USD 9514.4 Million in 2030, growing at a CAGR of 6.50% between 2023 and 2030.
  • This category may dominate the market for prophylaxis, with the therapy sector taking the lead.
  • Corticosteroids are another key therapeutic category in the market, with 5-HT3 Receptor Antagonists and NK1 Receptor Antagonists expected to have significant market shares.
  • Nausea and vomiting caused by chemotherapy (CINV) Therapeutics is the fastest growing industry, and the Chemotherapy Regimen industry is likewise a significant and growing business.
  • Oral drugs are frequently in more demand than intravenous (IV) medications, and another category is transdermal (Patch) pharmaceuticals.
  • Generic drugs are frequently in higher demand, while Branded drugs are another market segment.
  • Adults have a larger market share, whereas Pediatrics are another component of the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market.
  • North America will account for 40% of the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market by 2022, with the Asia Pacific region expected to have the highest compound annual growth rate.
  • The rising frequency of cancer and chemotherapy treatment promotes market expansion.
  • Variability in patient response to antiemetic drugs impedes market growth.

Chemotherapy-Induced Nausea and Vomiting Therapeutics Market (1)

Executive Summary

Market Definition

The Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market includes drugs and treatments that are specifically designed to alleviate and prevent nausea and vomiting caused by chemotherapy. It focuses on delivering efficient methods for managing chemotherapy side effects, which can include severe nausea and vomiting. To reduce CINV and enhance the quality of life for cancer patients receiving chemotherapy, a variety of pharmacological medications, such as antiemetic medications, are on the market.

Market Overview

The global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market has been steadily growing in recent years and is predicted to grow at a 6.50% CAGR between 2023 and 2030. The market is anticipated to be worth USD 9514.4 million by 2030, up from USD 5748.9 million in 2022.

The Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market is a growing market that focuses on providing drugs and treatments to assist reduce and prevent chemotherapy-induced nausea and vomiting. The market is being driven by the rising number of cancer patients receiving chemotherapy as well as the need for effective therapies to control side effects.

The rising prevalence of cancer worldwide, which leads to increased demand for chemotherapy, is one of the primary drivers of this market. As more patients get chemotherapy, the frequency of CINV rises, necessitating the development of medicines capable of effectively controlling these symptoms.

There are also certain constraints in this sector. The heterogeneity in individual patient responses to antiemetic drugs is one of the most difficult challenges. Different patients may be more or less susceptible to CINV, and determining the best treatment strategy can be difficult. Furthermore, the cost of CINV treatments can be prohibitive for some patients, particularly in areas with limited access to healthcare resources.

The CINV therapeutics industry offers potential. Research & development advances have resulted in the launch of new and more effective antiemetic drugs. Furthermore, personalized medicine, which tries to adjust treatment techniques based on unique patient characteristics, is gaining traction. This tailored strategy may aid in increasing the efficacy of CINV treatments and improving patient outcomes.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Segmentation by CINV Prophylaxis vs. Treatment

  • The market for prophylaxis may be dominated by this category. Prophylaxis focuses on preventing CINV before it happens, generally by using antiemetic drugs prior to chemotherapy. This method tries to reduce the frequency and intensity of nausea and vomiting in patients.
  • The treatment segment  may take the lead. Treatment include controlling existing CINV symptoms, which is frequently accomplished via the use of rescue drugs or alternative treatment techniques.

Segmentation by Drug Classes

  • 5-HT3 Receptor Antagonists and NK1 Receptor Antagonists are predicted to have sizable market shares attributed to their efficacy in controlling CINV symptoms.
  • Corticosteroids are another major therapeutic category in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market.

Segmentation by Patient Risk Profile

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics is the fastest expanding sector. Market conditions might change depending on market trends and emerging healthcare practices. However, the High-Risk Patient category is frequently regarded as having tremendous development potential.
  • The Chemotherapy Regimen sector is also an important and developing market.

Segmentation by Administration Route     

  • Oral medications are often in more demand than intravenous (IV) medications. Patients prefer oral drugs because they are more convenient and can be taken at home, whereas IV medications are normally provided in a hospital facility.
  • Transdermal (Patch) Medications are another segment in the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market.

Segmentation by Branded vs. Generic Products

  • Generic medications are often in higher demand. Generic drugs are less expensive and more cost-effective than branded pharmaceuticals. They go through the same rigorous safety and efficacy testing and have the same active ingredients as their branded versions.
  • Branded Medications are another section of the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market.

Segmentation by Patient Age Group 

  • When compared to the Pediatrics category, the Adults segment has a bigger market share. This is partly because adult cancer patients utilize chemotherapy at a higher rate.
  • Pediatrics are another component in the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market.

Segmentation by Region

  • North America will account for 40% of the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market by 2022.
  • The market for therapeutics for chemotherapy-induced nausea and vomiting is expected to develop at the fastest compound annual rate in the Asia Pacific region.
  • The remaining demand for Chemotherapy-Induced Nausea and Vomiting Therapeutics is met by the remainder of the world, which includes Latin America, the Middle East, and Africa.

North America dominates the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market due to its sophisticated healthcare infrastructure and high cancer prevalence. The region is known for its well-established healthcare facilities and competence in cancer treatment, which adds to increased demand for CINV medicines. Furthermore, North America has a significant number of cancer patients undergoing chemotherapy, which increases the need for appropriate CINV care. The region’s rich pharmaceutical industry and research advances further contribute to its supremacy in the CINV Therapeutics Market.

Due to a number of factors, Asia Pacific is seeing the fastest growth in the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market. One explanation is the region’s rising cancer prevalence. Cancer rates in Asia Pacific have been rising, resulting in a larger patient population undergoing chemotherapy. As a result, there is a larger need for effective chemotherapy-induced nausea and vomiting control. Furthermore, the region’s improved healthcare infrastructure and access to healthcare services have contributed to better cancer detection and treatment, including the use of CINV therapies. Because of the region’s increasing economy and increased disposable incomes, sophisticated cancer therapies are now more available to a bigger population.

Key Highlights of the Report

The global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market is segmented by CINV Prophylaxis vs. Treatment, Drug Classes, Patient Risk Profile, Administration Route, Branded vs. Generic Products, Patient Age Group and region. This category may dominate the prophylactic market. Additionally, 5-HT3 Receptor Antagonists and NK1 Receptor Antagonists are expected to have significant market shares. Nausea and vomiting caused by chemotherapy (CINV) Therapeutics is the fastest growing industry, and generic medications are frequently in great demand., with North America leading the market growth.

The primary drivers of the market are rising cancer and chemotherapy treatment prevalence, rising demand for efficient CINV therapies, and advancements in research and development. Furthermore, the market is confronted with important constraints such as variability in patient responses to antiemetic drugs, the high cost of CINV treatments, and limited access to healthcare resources in certain countries.

Nonetheless, North America dominates the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market due to its modern healthcare infrastructure and high cancer prevalence. The region is well-known for its well-established healthcare facilities and expertise in cancer treatment, which contributes to rising demand for CINV drugs. Furthermore, due to a variety of reasons, Asia Pacific is seeing the fastest growth in the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market. One cause is the region’s increasing cancer prevalence.

What Factors Are Fueling The Growth Of The Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market?

Several variables influence the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market. Cancer is becoming more common worldwide, increasing the demand for chemotherapy. The frequency of CINV rises as more individuals get chemotherapy. In addition, there is an increasing demand for efficient CINV therapies to address treatment adverse effects. Patients and healthcare providers are looking for methods to reduce and prevent nausea and vomiting. Furthermore, advances in research and development have resulted in the introduction of new and improved antiemetic drugs, giving patients more alternatives for CINV management.

What Are The Key Challenges Encountered By The Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market?

While the CINV Therapeutics Market appears to be promising, there are several obstacles to consider. The heterogeneity in patient responses to antiemetic medicines is a substantial constraint. Individuals may be more or less susceptible to CINV, making it difficult to discover the most effective treatment technique for each patient. Furthermore, the cost of CINV treatments can be prohibitively expensive for some patients, particularly in areas with limited access to healthcare resources. To guarantee fair access to therapy, the affordability and availability of these medications must be addressed.

What Opportunities For Growth Exist In The Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market?

Despite these constraints, the CINV Therapeutics Market offers chances for growth and advancement. One opportunity is the emphasis on individualized medicine. Treatment techniques that are tailored to specific patient features can assist improve the efficacy of CINV therapies and improve patient outcomes. Furthermore, ongoing research and development activities are developing the subject. This includes the development of new and more effective antiemetic drugs, which will provide improved options for CINV management. Exploration of novel therapeutic modalities and approaches also opens up new avenues for advancement in the discipline.

Market Drivers

The global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market is driven by several factors. The following are the key drivers of the global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market:

Increasing Prevalence Of Cancer And Chemotherapy Treatment

The rising prevalence of cancer and chemotherapy treatment is propelling the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market forward. Cancer cases have increased in different regions of the world, particularly the Asia Pacific region, in recent years. This is due to a variety of variables, including changing lifestyles, environmental issues, and an aging population.

Chemotherapy is a popular cancer treatment that, while efficient in attacking cancer cells, frequently causes side effects such as nausea and vomiting. These symptoms can have a major influence on the quality of life of chemotherapy patients, making CINV treatment an important element of cancer care.

As the number of cancer patients undergoing chemotherapy grows, so does the need for effective CINV treatments to reduce these adverse effects. To address this need, pharmaceutical companies are investing in the development of new and improved CINV treatments. These therapies aim to improve nausea and vomiting control, allowing patients to tolerate and complete chemotherapy treatments more pleasantly.

Market Restraints

The global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market faces some challenges that may hinder its growth. These include the following:

Variability In Patient Response To Antiemetic Medications  

Patient response variability to antiemetic drugs is a substantial restriction in the Chemotherapy-Induced Nausea and Vomiting (CINV) therapies industry. The body of each patient may react differently to various drugs, resulting in varied levels of efficacy in controlling CINV symptoms.

Individual variances in metabolism, genetic variants, and other patient-specific variables can all contribute to this variability. What works for one patient may not work for another, making it difficult to determine the best effective antiemetic medication for each person.

This constraint makes it difficult for healthcare practitioners to choose the best antiemetic drug and dose for their patients. It may necessitate a trial-and-error method in which different drugs or combinations are evaluated until the best choice is discovered.

Opportunities

The global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market offers significant growth opportunities. These include the following:

Focus On Personalized Medicine

The ability to focus on individualized medication in the Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Market is revolutionary! Individual patient features, such as genetic variants and metabolism, are taken into consideration in personalized medicine to create treatment programs individually for each patient.

Healthcare providers can better understand the specific elements that contribute to a patient’s response to CINV treatments by using a customized medicine strategy. This knowledge enables more accurate and effective treatment techniques, reducing the chance of unwanted effects while optimizing therapeutic success.

With advances in medical science and technology, one can now study a patient’s genetic profile and uncover specific indicators that may influence their reaction to antiemetic drugs. This knowledge enables healthcare practitioners to make informed decisions regarding the best treatment options for each patient, increasing the likelihood of effective CINV therapy.

Furthermore, personalized medicine in the CINV therapeutics market provides the way to novel medicines and tailored interventions. Pharmaceutical companies are investing in research and development to offer more tailored treatment choices that can target the specific needs of individual patients.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Competitive Landscape

Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Competitive (1)

Key Players

With multiple major companies, the global market for therapies to treat nausea and vomiting brought on by chemotherapy is quite competitive. Some of the major players in the market and their market share are as follows:

  • Kyowa Kirin, Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • AbbVie Inc. (Allergan plc)
  • Merck & Co., Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Camurus AB
  • Heron Therapeutics, Inc.

These organizations prioritize product innovation, Disease Area expansion, and mergers and acquisitions to stay competitive.

The global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market’s key players continually seek to stay ahead by offering new CINV Prophylaxis vs. Treatments and developments.

In September 2021, Merck announced the acquisition of Acceleron Pharma for $11.5 billion, taking ownership of Sotatercept, which is used to treat pulmonary hypertension, and luspatercept-aamt.

In April 2023,  Pfizer announced the relocation of its worldwide headquarters from Midtown Manhattan’s 42nd Street to the Spiral at Hudson Yards.

In November 2020, When tested on 43,500 individuals, Pfizer discovered that BioNTech’s COVID-19 vaccine was 90% effective in preventing symptomatic COVID-19. The effectiveness was increased to 95% a week later. According to Akiko Iwasaki, an immunologist contacted by the New York Times, the effectiveness statistic is “really a spectacular number.” According to the statement, Pfizer and BioNTech were the first companies to develop and test a COVID-19 vaccine.

Summary of Key Findings

  • Patient response variability to antiemetic medicines impedes market growth.
  • Market segmented by CINV Prophylaxis vs. Treatment, Drug Classes, Patient Risk Profile, Administration Route, Branded vs. Generic Products, Patient Age Group and region.
  • The High-Risk Patient category is frequently regarded as having great development potential
  • Oral medications are frequently in more demand than intravenous (IV) medications
  • North America is leading market growth; the market is highly competitive with key players including Kyowa Kirin, Inc., Pfizer Inc., AbbVie Inc. (Allergan plc), GlaxoSmithKline plc., Merck & Co., Inc., Bausch Health Companies Inc.

Future Outlook

  • Increasing cancer and chemotherapy treatment prevalence
  • Increasing demand for efficient CINV medicines
  • Research and development advancements
  • Focus on customized medicine
  • Potential for improved health outcomes
  • Challenges in patient response variability and therapeutic cost

Segmentation

  • By CINV Prophylaxis vs. Treatment:
    • Prophylaxis
    • Treatment
  • By Drug Classes:
    • 5-HT3 Receptor Antagonists
    • NK1 Receptor Antagonists
    • Corticosteroids
    • Benzodiazepines
    • Other Antiemetics
  • By Patient Risk Profile:
    • High-Risk Patients
    • Low-Risk Patients
    • Chemotherapy Regimen
  • By Administration Route:
    • Oral Medications
    • Intravenous (IV) Medications
  • By Branded vs. Generic Products:
    • Branded Medications
    • Generic Medications
  • By Patient Risk Profile:
    • Adults
    • Pediatrics
  • By Region
    • North America
      • U.S
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • South-east Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East and Africa

Adjacent Markets

In the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, there are several adjacent markets which has high revenue growth opportunities. The key adjacent markets for Chemotherapy-Induced Nausea and Vomiting Therapeutics Market-

Chemotherapy-Induced Nausea and Vomiting Therapeutics Market adjacent (1)

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction

2. Executive Summary
2.1. Market Snapshot: Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
2.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By CINV Prophylaxis vs. Treatment
2.1.2. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Drug Classes
2.1.3. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Patient Risk Profile
2.1.4. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Administration Route
2.1.5. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Branded vs. Generic Products
2.1.6. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Patient Risk Profile
2.1.7. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Region
2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Value, 2017-2030, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Drivers
3.2.2. Chemotherapy-Induced Nausea and Vomiting TherapeuticsMarket Restraints
3.2.3. Chemotherapy-Induced Nausea and Vomiting TherapeuticsMarket Opportunities
3.2.4. Major Chemotherapy-Induced Nausea and Vomiting Therapeutics Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. CINV Prophylaxis vs. Treatment
3.5.2. Drug Classes
3.5.3. Patient Risk Profile
3.5.4. Administration Route
3.5.5. Branded vs. Generic Products
3.5.6. Patient Risk Profile
3.5.7. Geography

4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2022
4.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market: Company Market Share, Value 2022
4.1.2. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market: Top 6 Company Market Share, Value 2022
4.1.3. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market: Top 3 Company Market Share, Value 2022
4.2. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market: Company Revenue Share Analysis, 2022
4.3. Company Assessment Metrics, 2022
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2022
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market

5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022
6.1. Company market share of key players, 2022
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others

7. Impact Analysis of COVID 19 and Russia – Ukraine War on Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa

8. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By CINV Prophylaxis vs. Treatment
8.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Overview, by CINV Prophylaxis vs. Treatment
8.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Revenue Share, By CINV Prophylaxis vs. Treatment, 2022 Vs 2030 (in %)
8.2. Prophylaxis
8.2.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By PROPHYLAXIS, By Region, 2017-2030 (US$ Mn)
8.2.2. Market Dynamics for PROPHYLAXIS
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Treatment
8.3.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Treatment, By Region, 2017-2030 (US$ Mn)
8.3.2. Market Dynamics for Treatment
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends

9. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Drug Classes
9.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Overview, by Drug Classes
9.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Revenue Share, By Drug Classes, 2022 Vs 2030 (in %)
9.2. 5-HT3 Receptor Antagonists
9.2.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By 5-HT3 Receptor Antagonists, By Region, 2017-2030 (US$ Mn)
9.2.2. Market Dynamics for 5-HT3 Receptor Antagonists
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. NK1 Receptor Antagonists
9.3.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By NK1 Receptor Antagonists, By Region, 2017-2030 (US$ Mn)
9.3.2. Market Dynamics for NK1 Receptor Antagonists
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Corticosteroids
9.4.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Corticosteroids, By Region, 2017-2030 (US$ Mn)
9.4.2. Market Dynamics for Corticosteroids
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends

10. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Patient Risk Profile
10.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Overview, by Patient Risk Profile
10.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Revenue Share, By Patient Risk Profile, 2022 Vs 2030 (in %)
10.2. High-Risk Patients
10.2.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By High-Risk Patients, By Region, 2017-2030 (US$ Mn)
10.2.2. Market Dynamics for High-Risk Patients
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Low-Risk Patients
10.3.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Low-Risk Patients, By Region, 2017-2030 (US$ Mn)
10.3.2. Market Dynamics for Low-Risk Patients
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends

11. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Administration Route
11.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Overview, by Administration Route
11.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Revenue Share, By Administration Route, 2022 Vs 2030 (in %)
11.2. Branded Medications
11.2.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Branded Medications, By Region, 2017-2030 (US$ Mn)
11.2.2. Market Dynamics for Branded Medications
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Intravenous (IV) Medications
11.3.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Intravenous (IV) Medications, By Region, 2017-2030 (US$ Mn)
11.3.2. Market Dynamics for Intravenous (IV) Medications
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends

12. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Branded vs. Generic Products
12.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Overview, by Branded vs. Generic Products
12.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Revenue Share, By Branded vs. Generic Products, 2022 Vs 2030 (in %)
12.2. Branded Medications
12.2.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Branded Medications, By Region, 2017-2030 (US$ Mn)
12.2.2. Market Dynamics for Branded Medications
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Generic Medications
12.3.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Generic Medications, By Region, 2017-2030 (US$ Mn)
12.3.2. Market Dynamics for Generic Medications
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends

13. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Patient Risk Profile
13.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Overview, by Patient Risk Profile
13.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Revenue Share, By Patient Risk Profile, 2022 Vs 2030 (in %)
13.2. Adults
13.2.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Adults, By Region, 2017-2030 (US$ Mn)
13.2.2. Market Dynamics for Adults
13.2.2.1. Drivers
13.2.2.2. Restraints
13.2.2.3. Opportunities
13.2.2.4. Trends
13.3. Pediatrics
13.3.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Pediatrics, By Region, 2017-2030 (US$ Mn)
13.3.2. Market Dynamics for Pediatrics
13.3.2.1. Drivers
13.3.2.2. Restraints
13.3.2.3. Opportunities
13.3.2.4. Trends

14. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Region
14.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Overview, by Region
14.1.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Region, 2022 vs 2030 (in%)
14.2. CINV Prophylaxis vs. Treatment
14.2.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By CINV Prophylaxis vs. Treatment, 2017-2030 (US$ Mn)
14.3. Drug Classes
14.3.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Drug Classes, 2017-2030 (US$ Mn)
14.4. Patient Risk Profile
14.4.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Patient Risk Profile, 2017-2030 (US$ Mn)
14.5. Administration Route
14.5.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Administration Route, 2017-2030 (US$ Mn)
14.6. Branded vs. Generic Products
14.6.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Branded vs. Generic Products, 2017-2030 (US$ Mn)
14.7. Patient Risk Profile
14.7.1. Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, By Patient Risk Profile, 2017-2030 (US$ Mn)

15. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Analysis
15.1. Overview
15.1.1. Market Dynamics for North America
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2030(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2030(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, 2017-2030(US$ Mn)
15.5.1. Overview
15.5.2. SRC Analysis
15.6. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2030(US$ Mn)
15.6.1. Overview
15.6.2. SRC Analysis
15.7. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
15.7.1. Overview
15.7.2. SRC Analysis
15.8. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2030(US$ Mn)
15.8.1. North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2022 Vs 2030 (in%)
15.8.2. U.S.
15.8.3. Canada
15.8.4. Mexico

16. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Analysis
16.1. Overview
16.1.1. Market Dynamics for North America
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2030(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2030(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, 2017-2030(US$ Mn)
16.5.1. Overview
16.5.2. SRC Analysis
16.6. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2030(US$ Mn)
16.6.1. Overview
16.6.2. SRC Analysis
16.7. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
16.7.1. Overview
16.7.2. SRC Analysis
16.8. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2030 (US$ Mn)
16.8.1. Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2022 Vs 2030 (in%)
16.8.2. UK
16.8.3. France
16.8.4. Germany
16.8.5. Italy
16.8.6. Spain
16.8.7. Benelux
16.8.8. Russia
16.8.9. Rest of Europe

17. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Analysis
17.1. Overview
17.1.1. Market Dynamics for North America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2030(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2030(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, 2017-2030(US$ Mn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2030(US$ Mn)
17.6.1. Overview
17.6.2. SRC Analysis
17.7. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
17.7.1. Overview
17.7.2. SRC Analysis
17.8. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2030 (US$ Mn)
17.8.1. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2022 Vs 2030 (in%)
17.8.2. China
17.8.3. Japan
17.8.4. India
17.8.5. South Korea
17.8.6. South East Asia
17.8.7. Rest of Asia Pacific

18. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Analysis
18.1. Overview
18.1.1. Market Dynamics for North America
18.1.1.1. Drivers
18.1.1.2. Restraints
18.1.1.3. Opportunities
18.1.1.4. Trends
18.2. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2030(US$ Mn)
18.2.1. Overview
18.2.2. SRC Analysis
18.3. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2030(US$ Mn)
18.3.1. Overview
18.3.2. SRC Analysis
18.4. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
18.4.1. Overview
18.4.2. SRC Analysis
18.5. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, 2017-2030(US$ Mn)
18.5.1. Overview
18.5.2. SRC Analysis
18.6. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2030(US$ Mn)
18.6.1. Overview
18.6.2. SRC Analysis
18.7. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
18.7.1. Overview
18.7.2. SRC Analysis
18.8. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2030 (US$ Mn)
18.8.1. Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2022 Vs 2030 (in%)
18.8.2. Brazil
18.8.3. Argentina
18.8.4. Rest of Latin America

19. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Analysis
19.1. Overview
19.1.1. Market Dynamics for North America
19.1.1.1. Drivers
19.1.1.2. Restraints
19.1.1.3. Opportunities
19.1.1.4. Trends
19.2. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2030(US$ Mn)
19.2.1. Overview
19.2.2. SRC Analysis
19.3. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2030(US$ Mn)
19.3.1. Overview
19.3.2. SRC Analysis
19.4. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
19.4.1. Overview
19.4.2. SRC Analysis
19.5. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, 2017-2030(US$ Mn)
19.5.1. Overview
19.5.2. SRC Analysis
19.6. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2030(US$ Mn)
19.6.1. Overview
19.6.2. SRC Analysis
19.7. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
19.7.1. Overview
19.7.2. SRC Analysis
19.8. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2030 (US$ Mn)
19.8.1. Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2022 Vs 2030 (in%)
19.8.2. UAE
19.8.3. Saudi Arabia
19.8.4. Rest of Middle East

20. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Analysis
20.1. Overview
20.1.1. Market Dynamics for North America
20.1.1.1. Drivers
20.1.1.2. Restraints
20.1.1.3. Opportunities
20.1.1.4. Trends
20.2. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2030(US$ Mn)
20.2.1. Overview
20.2.2. SRC Analysis
20.3. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2030(US$ Mn)
20.3.1. Overview
20.3.2. SRC Analysis
20.4. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
20.4.1. Overview
20.4.2. SRC Analysis
20.5. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, 2017-2030(US$ Mn)
20.5.1. Overview
20.5.2. SRC Analysis
20.6. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2030(US$ Mn)
20.6.1. Overview
20.6.2. SRC Analysis
20.7. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2030(US$ Mn)
20.7.1. Overview
20.7.2. SRC Analysis
20.8. Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2030 (US$ Mn)
20.8.1. Middle EastChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2022 Vs 2030 (in%)
20.8.2. South Africa
20.8.3. Egypt
20.8.4. Rest of Africa

21. Company Profiles
21.1. Kyowa Kirin, Inc.
21.1.1. Company Overview
21.1.2. Products/Services Portfolio
21.1.3. Geographical Presence
21.1.4. SWOT Analysis
21.1.5. Financial Summary
21.1.5.1. Market Revenue and Net Profit (2019-2022)
21.1.5.2. Business Segment Revenue Analysis
21.1.5.3. Geographical Revenue Analysis
21.2. Pfizer Inc.
21.3. GlaxoSmithKline plc.
21.4. AbbVie Inc. (Allergan plc)
21.5. Merck & Co., Inc.
21.6. Bausch Health Companies Inc.
21.7. Novartis AG
21.8. Ono Pharmaceutical Co., Ltd.
21.9. Camurus AB
21.10. Heron Therapeutics, Inc.

22. Research Methodology
22.1. Research Methodology
22.2. Phase I – Secondary Research
22.3. Phase II – Data Modelling
22.3.1. Company Share Analysis Model
22.3.2. Revenue Based Modelling
22.4. Phase III – Primary Research
22.5. Research Limitations
22.5.1. Assumptions

List of Figures
FIG. 1 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Segmentation
FIG. 4 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2022 (US$ Mn)
FIG. 5 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2022 (US$ Mn)
FIG. 6 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2022 (US$ Mn)
FIG. 7 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, 2022 (US$ Mn)
FIG. 8 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2022 (US$ Mn)
FIG. 9 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2022 (US$ Mn)
FIG. 10 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Geography, 2022 (US$ Mn)
FIG. 11 Attractive Investment Proposition, by CINV Prophylaxis vs. Treatment, 2022
FIG. 12 Attractive Investment Proposition, by Drug Classes, 2022
FIG. 13 Attractive Investment Proposition, by Patient Risk Profile, 2022
FIG. 14 Attractive Investment Proposition, by Administration Route, 2022
FIG. 15 Attractive Investment Proposition, by Branded vs. Generic Products, 2022
FIG. 16 Attractive Investment Proposition, by Patient Risk Profile, 2022
FIG. 17 Attractive Investment Proposition, by Geography, 2022
FIG. 18 Global Market Share Analysis of Key Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Manufacturers, 2022
FIG. 19 Global Market Positioning of Key Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Manufacturers, 2022
FIG. 20 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Value Contribution, By CINV Prophylaxis vs. Treatment, 2022 & 2030 (Value %)
FIG. 21 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by PROPHYLAXIS, Value, 2017-2030 (US$ Mn)
FIG. 22 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Treatment, Value, 2017-2030 (US$ Mn)
FIG. 23 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Sun Protection Products, Value, 2017-2030 (US$ Mn)
FIG. 24 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by 5-HT3 Receptor Antagonists Products, Value, 2017-2030 (US$ Mn)
FIG. 25 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Value Contribution, By Drug Classes, 2022 & 2030 (Value %)
FIG. 26 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by 5-HT3 Receptor Antagonists, Value, 2017-2030 (US$ Mn)
FIG. 27 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by NK1 Receptor Antagonists, Value, 2017-2030 (US$ Mn)
FIG. 28 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Corticosteroids, Value, 2017-2030 (US$ Mn)
FIG. 29 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Value Contribution, By Patient Risk Profile, 2022 & 2030 (Value %)
FIG. 30 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by High-Risk Patients, Value, 2017-2030 (US$ Mn)
FIG. 31 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Low-Risk Patients, Value, 2017-2030 (US$ Mn)
FIG. 32 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Value Contribution, By Administration Route, 2022 & 2030 (Value %)
FIG. 33 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, Value, 2017-2030 (US$ Mn)
FIG. 34 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Intravenous (IV) Medications, Value, 2017-2030 (US$ Mn)
FIG. 35 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Value Contribution, By Branded vs. Generic Products, 2022 & 2030 (Value %)
FIG. 36 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, Value, 2017-2030 (US$ Mn)
FIG. 37 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Generic Medications, Value, 2017-2030 (US$ Mn)
FIG. 38 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Value Contribution, By Patient Risk Profile, 2022 & 2030 (Value %)
FIG. 39 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, Value, 2017-2030 (US$ Mn)
FIG. 40 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Generic Medications, Value, 2017-2030 (US$ Mn)
FIG. 41 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Gum Health, Value, 2017-2030 (US$ Mn)
FIG. 42 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 43 U.S. Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 44 Canada Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 45 Mexico Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 46 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 47 Germany Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 48 France Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 49 U.K. Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 50 Italy Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 51 Spain Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 52 Benelux Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 53 Russia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 54 Rest of Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 55 Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 56 China Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 57 Japan Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 58 India Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 59 South Korea Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 60 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 61 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 62 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 63 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 64 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 65 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 66 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 67 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 68 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 69 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 70 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 71 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 72 EgyptChemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)
FIG. 73 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, 2017-2030 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
TABLE 2 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market: Market Drivers Impact Analysis
TABLE 3 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market: Market Restraints Impact Analysis
TABLE 4 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Competitive Benchmarking, 2022
TABLE 5 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Key Strategies Analysis, 2022
TABLE 7 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by PROPHYLAXIS, By Region, 2017-2022 (US$ Mn)
TABLE 8 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by PROPHYLAXIS, By Region, 2023-2030 (US$ Mn)
TABLE 9 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Treatment, By Region, 2017-2022 (US$ Mn)
TABLE 10 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Treatment, By Region, 2023-2030 (US$ Mn)
TABLE 11 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Sun Protection Products, By Region, 2017-2022 (US$ Mn)
TABLE 12 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Sun Protection Products, By Region, 2023-2030 (US$ Mn)
TABLE 13 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by 5-HT3 Receptor Antagonists Products, By Region, 2017-2022 (US$ Mn)
TABLE 14 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by 5-HT3 Receptor Antagonists Products, By Region, 2023-2030 (US$ Mn)
TABLE 15 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by 5-HT3 Receptor Antagonists, By Region, 2017-2022 (US$ Mn)
TABLE 16 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by 5-HT3 Receptor Antagonists, By Region, 2023-2030 (US$ Mn)
TABLE 17 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by NK1 Receptor Antagonists, By Region, 2017-2022 (US$ Mn)
TABLE 18 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by NK1 Receptor Antagonists, By Region, 2023-2030 (US$ Mn)
TABLE 19 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Corticosteroids, By Region, 2017-2022 (US$ Mn)
TABLE 20 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Corticosteroids, By Region, 2023-2030 (US$ Mn)
TABLE 21 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by High-Risk Patients, By Region, 2017-2022 (US$ Mn)
TABLE 22 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by High-Risk Patients, By Region, 2023-2030 (US$ Mn)
TABLE 23 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Low-Risk Patients, By Region, 2017-2022 (US$ Mn)
TABLE 24 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Low-Risk Patients, By Region, 2023-2030 (US$ Mn)
TABLE 25 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, By Region, 2017-2022 (US$ Mn)
TABLE 26 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, By Region, 2023-2030 (US$ Mn)
TABLE 27 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Intravenous (IV) Medications, By Region, 2017-2022 (US$ Mn)
TABLE 28 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Intravenous (IV) Medications, By Region, 2023-2030 (US$ Mn)
TABLE 29 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, By Region, 2023-2030 (US$ Mn)
TABLE 30 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, By Region, 2017-2022 (US$ Mn)
TABLE 31 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Generic Medications, By Region, 2023-2030 (US$ Mn)
TABLE 32 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Generic Medications, By Region, 2017-2022 (US$ Mn)
TABLE 33 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, By Region, 2017-2022 (US$ Mn)
TABLE 34 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded Medications, By Region, 2023-2030 (US$ Mn)
TABLE 35 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Generic Medications, By Region, 2017-2022 (US$ Mn)
TABLE 36 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Generic Medications, By Region, 2023-2030 (US$ Mn)
TABLE 37 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Gum Health, By Region, 2017-2022 (US$ Mn)
TABLE 38 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Gum Health, By Region, 2023-2030 (US$ Mn)
TABLE 39 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 40 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 41 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 42 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 43 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 44 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 45 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 46 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 47 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 48 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 49 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 50 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 51 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Region, 2017-2022 (US$ Mn)
TABLE 52 Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Region, 2023-2030 (US$ Mn)
TABLE 53 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 54 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 55 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 56 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 57 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 58 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 59 North AmericaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 60 North AmericaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 61 North AmericaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 62 North AmericaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 63 North AmericaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 64 North AmericaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 65 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2022 (US$ Mn)
TABLE 66 North America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2023-2030 (US$ Mn)
TABLE 67 United States Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 68 United States Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 69 United States Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 70 United States Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 71 United States Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 72 United States Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 73 United StatesChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 74 United StatesChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 75 United StatesChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 76 United StatesChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 77 United StatesChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 78 United StatesChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 79 Canada Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 80 Canada Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 81 Canada Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 82 Canada Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 83 Canada Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 84 Canada Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 85 CanadaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 86 CanadaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 87 CanadaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 88 CanadaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 89 CanadaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 90 CanadaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 91 Mexico Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 92 Mexico Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 93 Mexico Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 94 Mexico Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 95 Mexico Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 96 Mexico Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 97 MexicoChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 98 MexicoChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 99 MexicoChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 100 MexicoChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 101 MexicoChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 102 MexicoChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 103 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 104 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 105 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 106 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 107 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 108 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 109 EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 110 EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 111 EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 112 EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 113 EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 114 EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 115 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2017-2022 (US$ Mn)
TABLE 116 Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Country, 2023-2030 (US$ Mn)
TABLE 117 Germany Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 118 Germany Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 119 Germany Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 120 Germany Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 121 Germany Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 122 Germany Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 123 GermanyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 124 GermanyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 125 GermanyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 126 GermanyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 127 GermanyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 128 GermanyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 129 France Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 130 France Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 131 France Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 132 France Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 133 France Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 134 France Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 135 FranceChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 136 FranceChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 137 FranceChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 138 FranceChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 139 FranceChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 140 FranceChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 141 United Kingdom Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 142 United Kingdom Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 143 United Kingdom Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 144 United Kingdom Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 145 United Kingdom Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 146 United Kingdom Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 147 United KingdomChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 148 United KingdomChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 149 United KingdomChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 150 United KingdomChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 151 United KingdomChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 152 United KingdomChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 153 Italy Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 154 Italy Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 155 Italy Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 156 Italy Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 157 Italy Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 158 Italy Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 159 ItalyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 160 ItalyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 161 ItalyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 162 ItalyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 163 ItalyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 164 ItalyChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 165 Spain Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 166 Spain Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 167 Spain Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 168 Spain Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 169 Spain Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 170 Spain Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 171 SpainChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 172 SpainChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 173 SpainChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 174 SpainChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 175 SpainChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 176 SpainChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 177 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 178 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 179 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 180 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 181 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 182 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 183 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 184 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 185 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 186 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 187 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 188 BeneluxChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 189 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 190 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 191 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 192 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 193 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 194 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 195 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 196 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 197 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 198 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 199 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 200 RussiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 201 Rest of Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 202 Rest of Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 203 Rest of Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 204 Rest of Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 205 Rest of Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 206 Rest of Europe Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 207 Rest of EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 208 Rest of EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 209 Rest of EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 210 Rest of EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 211 Rest of EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 212 Rest of EuropeChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 213 Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 214 Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 215 Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 216 Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 217 Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 218 Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 219 Asia PacificChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 220 Asia PacificChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 221 Asia PacificChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 222 Asia PacificChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 223 Asia PacificChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 224 Asia PacificChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 225 China Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 226 China Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 227 China Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 228 China Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 229 China Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 230 China Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 231 ChinaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 232 ChinaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 233 ChinaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 234 ChinaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 235 ChinaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 236 ChinaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 237 Japan Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 238 Japan Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 239 Japan Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 240 Japan Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 241 Japan Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 242 Japan Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 243 JapanChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 244 JapanChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 245 JapanChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 246 JapanChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 247 JapanChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 248 JapanChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 249 India Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 250 India Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 251 India Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 252 India Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 253 India Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 254 India Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 255 IndiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 256 IndiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 257 IndiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 258 IndiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 259 IndiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 260 IndiaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 261 South Korea Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 262 South Korea Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 263 South Korea Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 264 South Korea Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 265 South Korea Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 266 South Korea Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 267 South KoreaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 268 South KoreaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 269 South KoreaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 270 South KoreaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 271 South KoreaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 272 South KoreaChemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 273 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 274 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 275 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 276 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 277 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 278 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 279 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 280 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 281 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 282 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 283 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 284 South-East Asia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 285 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 286 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 287 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 288 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 289 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 290 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 291 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 292 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 293 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 294 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 295 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 296 Rest of Asia Pacific Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 297 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 298 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 299 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 300 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 301 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 302 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 303 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 304 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 305 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 306 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 307 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 308 Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 309 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 310 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 311 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 312 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 313 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 314 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 315 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 316 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 317 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 318 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 319 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 320 Brazil Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 321 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 322 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 323 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 324 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 325 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 326 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 327 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 328 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 329 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 330 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 331 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 332 Argentina Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 333 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 334 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 335 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 336 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 337 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 338 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 339 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 340 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 341 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 342 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 343 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 344 Rest of Latin America Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 345 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 346 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 347 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 348 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 349 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 350 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 351 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 352 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 353 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 354 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 355 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 356 Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 357 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 358 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 359 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 360 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 361 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 362 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 363 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 364 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 365 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 366 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 367 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 368 UAE Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 369 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 370 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 371 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 372 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 373 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 374 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 375 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 376 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 377 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 378 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 379 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 380 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 381 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 382 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 383 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 384 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 385 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 386 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 387 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 388 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 389 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 390 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 391 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 392 Rest of Middle East Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 393 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 394 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 395 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 396 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 397 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 398 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 399 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 400 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 401 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 402 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 403 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 404 Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 405 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 406 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 407 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 408 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 409 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 410 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 411 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 412 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 413 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 414 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 415 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 416 South Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 417 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 418 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 419 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 420 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 421 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 422 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 423 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 424 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 425 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 426 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 427 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 428 Egypt Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 429 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2017-2022 (US$ Mn)
TABLE 430 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by CINV Prophylaxis vs. Treatment, 2023-2030 (US$ Mn)
TABLE 431 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2017-2022 (US$ Mn)
TABLE 432 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Drug Classes, 2023-2030 (US$ Mn)
TABLE 433 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 434 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)
TABLE 435 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2017-2022 (US$ Mn)
TABLE 436 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Administration Route, By Region, 2023-2030 (US$ Mn)
TABLE 437 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2017-2022 (US$ Mn)
TABLE 438 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Branded vs. Generic Products, 2023-2030 (US$ Mn)
TABLE 439 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2017-2022 (US$ Mn)
TABLE 440 Rest of Africa Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, by Patient Risk Profile, 2023-2030 (US$ Mn)

Frequently Asked Question

What is the current size of the worldwide Chemotherapy-Induced Nausea and Vomiting Therapeutics Market?

In 2022, the global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market is expected to be worth USD 5748.9 million.

What is the predicted growth rate of the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market between 2023 and 2030?

The Chemotherapy-Induced Nausea and Vomiting Therapeutics Market is estimated to increase at a CAGR of 6.50% between 2023 and 2030, reaching USD 9514.4 Million in 2030.

Which segment has the most market share in terms of CINV Prophylaxis vs. Treatment?

This category may dominate the market for prophylaxis

Which administration route segment governs the market demand for Chemotherapy-Induced Nausea and Vomiting Therapeutics ?

Oral medications are frequently in more demand than intravenous (IV) medications

Which patient risk profile segment is the fastest growing segment in the market over the forecast period?

The High-Risk Patient category is frequently regarded as having great development potential.

Which region is driving the Chemotherapy-Induced Nausea and Vomiting Therapeutics industry forward?

North America will account for 40% of the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market by 2022

Who are the major players in the global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market?

The top players include Kyowa Kirin, Inc., Pfizer Inc., AbbVie Inc. (Allergan plc), GlaxoSmithKline plc., Merck & Co., Inc., Bausch Health Companies Inc.

What are the major market drivers of the Chemotherapy-Induced Nausea and Vomiting Therapeutics industry?

The primary market drivers are rising cancer and chemotherapy treatment prevalence, rising demand for efficient CINV therapies, and advancements in research and development.

What are the major market restraints of the Chemotherapy-Induced Nausea and Vomiting Therapeutics industry?

The market’s main obstacles are variability in patient responses to antiemetic drugs, the high cost of CINV treatments, and limited access to healthcare resources in certain countries.

What are the major market opportunities of the Chemotherapy-Induced Nausea and Vomiting Therapeutics industry?

The primary opportunity in the market is the focus on customized treatment, the introduction of new and more effective antiemetic drugs, and ongoing research and development initiatives.

Antineoplastic Agents Market

Published:
Report ID: 36065

US Retail Pharmacy Market

Published:
Report ID: 32801

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

OTC Cough Cold And Allergy Medicine Market

Published:
Report ID: 20062

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN